Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bristol-Myers Squibb presents PD-1/PD-L1 interaction inhibitors

March 30, 2015

Immunovaccine begins phase II trial of DPX-Survivac immunotherapy in lymphoma

March 25, 2015

Scancell's SCIB-2 DNA vaccine synergizes with immune checkpoint inhibitors against tumor cells

March 24, 2015

Celdara Medical begins phase I trial of chimeric-antigen receptor T cells

March 24, 2015

Cell therapy for EBV-positive non-Hodgkin's lymphomas granted orphan status

March 23, 2015

Universitaet zu Koeln divulges anti-CD30 CAR T cells

March 20, 2015

Novogen reports on potential of Anisina to become new chemotherapy

March 19, 2015

ADC Therapeutics files IND for phase I trial of ADCT-301

March 17, 2015

ImMucin receives E.U. orphan drug designation for multiple myeloma

March 17, 2015

Altor Bioscience begins phase I/II study of ALT-803 indolent B-cell non-Hodgkin's lymphoma

March 17, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...